Melanoma-or Something Else?

News
Article

This week’s quiz questions challenge you to determine the cause of an infant’s “strange breathing” based on a chest film, to come up with the most common cause of chronic cough in children, to be a dermatologic detective, among other things.

Question 1:

NEXT QUESTION »


For the discussion, click here.


For the answer, click here.


 

 

Question 2:

NEXT QUESTION »


For the discussion, click here.


For the answer, click here.


 

 

Question 3:

NEXT QUESTION »


For the discussion, click here.


For the answer, click here.


 

Question 4:

NEXT QUESTION »


For the discussion, click here.


For the answer, click here.


 

 

Question 5:

ANSWER KEY »


For the discussion, click here.


 

ANSWER KEY:

Question 1. B

Question 2. A

Question 3. D

Question 4. C

Question 5. C

Recent Videos
Primary Care is the Answer to the Migraine Care Gap, Says Headache Specialist
Migraine Management Pearls for Primary Care with Neurologist Jessica Ailani, MD
Migraine-specific therapies belong in primary care setting, Jessica Ailani, MD
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Related Content
Why the OX-40/OX-40L Pathway Matters in Atopic Dermatitis—and What’s Next: A Q&A with Johann Gudjonsson, MD, PhD

Why the OX-40/OX-40L Pathway Matters in Atopic Dermatitis—and What’s Next: A Q&A with Johann Gudjonsson, MD, PhD

Sydney Jennings;Johann Gudjonsson, MD, PhD
June 12th 2025
Article

At RAD 2025, Johann Gudjonsson, MD, PhD, discussed the OX-40 pathway’s role in AD, genetic links to disease risk, and promising combination therapies in development.

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Sydney Jennings
May 7th 2025
Podcast

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD

Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD

Sydney Jennings
June 11th 2025
Article

RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.

Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

Sydney Jennings
April 6th 2023
Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Upadacitinib Shows Real-World Efficacy in Bio-Naïve, Bio-Experienced Adults with Atopic Dermatitis in New Study

Upadacitinib Shows Real-World Efficacy in Bio-Naïve, Bio-Experienced Adults with Atopic Dermatitis in New Study

Sydney Jennings
June 9th 2025
Article

RAD 2025: Many adults achieved optimal treatment targets with upadacitinib after 6 months, regardless of prior biologic therapy, according to new late-breaking data.

/Gil Yosipovitch, MD Courtesy of Miller School of Medicine

Q&A: Managing Chronic Itch With Renowned Investigator Gil Yosipovitch, MD

Gil Yosipovitch, MD;Grace Halsey
June 9th 2025
Article

RAD 2025: World expert on the pathophysiology of itch Gil Yosipovitch, MD, answers questions on the disease of chronic itch and on the expanding options for targeted treatment.

© 2025 MJH Life Sciences

All rights reserved.